Royal Medical Center review

Royal Medical Center publishes a starting monthly figure for compounded GLP-1 care, but that is a class-wide advertisement covering semaglutide and tirzepatide options. It does not identify which medicine, dose or program produces the starting price. That prevents a fair dollar-for-dollar comparison with a named-drug offer. The clinic may provide an attractive quote after evaluation, but the public figure alone cannot establish it. Before comparing Royal with the compounded tirzepatide lineup, request a written proposal naming the actual prescription, supply duration and total recurring charge. One-, two- and three-month programs are described on the injection page, making the length of the proposed purchase another detail to settle alongside the drug name.

What Royal explains more clearly is the intended bundle. Its weight-loss page includes a comprehensive health evaluation and lab testing, medication, physician consultations and follow-ups, lab monitoring and adjustments. That makes the offer broader than a prescription referral with every service billed afterward. It also gives you specific inclusions to check against the quote: which blood tests are covered, where you obtain them and whether follow-up appointments have any limits. The wording describes regular progress monitoring without giving a universal GLP-1 appointment calendar. Royal’s hormone-care FAQs discuss a more explicit monitoring routine, but that routine should not be transferred to weight care without confirmation. Ask the GLP-1 clinician to explain when you will be reviewed and how you can reach them if you have concerns before the next planned contact.

The clinic is centered in Deerfield Beach, Florida, with a street address and a published physician biography for Dr. Dagoberto Rodriguez. Royal names Belmar Pharma Solutions as its dispensing pharmacy in the footer. Naming a physician and a pharmacy gives patients businesses and professionals they can ask about, rather than leaving the whole service behind a generic promise of licensed care. It still does not identify who will handle every appointment or prove that every prescription is filled by the same facility. Confirm the treating clinician, the assigned dispensing location and whether the proposed care can take place remotely from your state. The public pages do not provide a clear served-state list or one standard telehealth visit format. A Florida clinic address establishes a local presence; it does not establish unrestricted nationwide access.

Royal’s GLP-1 product disclaimer distinguishes compounded preparations from approved branded medication and describes a state-licensed sterile compounding pharmacy partner. It also cautions that product photographs may not represent the actual medicine or package dispensed. Those distinctions are useful: the named molecule, formulation and pharmacy information in your prescription matter more than a product image. The compounded semaglutide guide explains the issues to discuss before accepting a fill. Royal’s broader catalog spans hormone programs and many peptides; availability in that menu is not a reason to combine them with weight treatment. In particular, products such as BPC-157, TB-500 and MOTS-C raise separate evidence and regulatory questions; their availability is not a reason to add them to weight treatment.

The offer becomes harder to assess at the exit. The publicly accessible information does not settle a complete cancellation deadline and refund schedule for the proposed GLP-1 program. An inquiry-based service can explain those details personally, but a patient should have them before paying, especially when choosing multiple months. Ask what is refunded before clinical work begins, before a prescription reaches the pharmacy and after medicine has been prepared. Also ask whether a follow-up prescription renews automatically or needs a new authorization. Use the semaglutide program comparison if you prefer to review detailed purchase terms before talking to a clinic. Royal has meaningful clinical and dispensing information in public view; its missing drug-specific price and exit terms still require a deliberate conversation.